US/UK/Canada

Share

Contacts

  • Mia Brundin

    CEO


    Vasagatan 28, 111 20 Stockholm
    +46 734 330 625

    • Links

    Pick a time period -
    Tags ( Active)

    Synartro has been granted regulatory and ethical approval for the first clinical trial of lead compound SYN321 for treatment of symptomatic knee osteoarthritis

    Synartro announces that the company has been granted approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the phase 1/2a first-in-human clinical study of the investigational drug candidate SYN321.The objective of the clinical study is to evaluate safety and tolerability, systemic exposure, and preliminary efficacy of SYN321 in patients with symptomatic knee osteoarthritis (OA). The phase 1/2a study will be conducted by Clinical Trial Consultants AB in Uppsala and is planned to start turn of the year 2023/2024. The lead candidate SYN321 is a

    Synartro prepares for first clinical trial of lead compound SYN321 for treatment of symptomatic knee osteoarthritis

    Synartro announced today that the company has submitted a clinical trial application to the Swedish Medical Products Agency and the Swedish Ethical Review Authority, for a phase 1/2a first-in-human clinical study of investigational drug candidate SYN321.The objective of the clinical study is to evaluate safety and tolerability, systemic exposure and preliminary efficacy of SYN321 in patients with symptomatic knee osteoarthritis (OA). The phase 1/2a study will be conducted by Clinical Trial Consultants AB in Uppsala and is planned to start during 2023. The lead candidate SYN321 is a joint

    Synartro granted European patent

    Synartro’s patent application for its drug delivery platform has been granted by the European Patent Office. The patent strengthens the position of the company’s lead candidate SYN321, which is developed for treatment of knee osteoarthritis. The granted patent also protects further development within other areas and indications based on the platform.The patent (European Patent No. 3226905) covers the company’s mechanism for linking hyaluronan with another active substance, as well as the method to produce the linking mechanism. With the patent, Synartro is given exclusivity in Europe until

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media